• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    4/11/24 1:33:07 PM ET
    $ACOR
    $AIH
    $AKAN
    $ALPN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ACOR alert in real time by email

    Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

    Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents.

    Fastenal shares dipped 6.7% to $69.73 on Thursday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Rallybio Corporation (NASDAQ:RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
    • Rent the Runway, Inc. (NASDAQ:RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance.
    • Eliem Therapeutics, Inc. (NASDAQ:ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement.
    • Akanda Corp. (NASDAQ:AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.
    • Alpine Immune Sciences, Inc. (NASDAQ:ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.
    • Candel Therapeutics, Inc. (NASDAQ:CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.
    • Enliven Therapeutics, Inc. (NASDAQ:ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
    • Selina Hospitality PLC (NASDAQ:SLNA) rose 21.1% to $0.0923.
    • Globavend Holdings Limited (NASDAQ:GVH) climbed 16.8% to $1.68.
    • Janux Therapeutics, Inc. (NASDAQ:JANX) gained 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.
    • SciSparc Ltd. (NASDAQ:SPRC) shares rose 15.3% to $1.9357.
    • Gyre Therapeutics, Inc. (NASDAQ:GYRE) gained 14.6% to $15.91.
    • AnaptysBio, Inc. (NASDAQ:ANAB) climbed 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.
    • Verb Technology Company, Inc. (NASDAQ:VERB) gained 10.4% to $0.2010 after gaining 4% on Wednesday.
    • GigaCloud Technology Inc. (NASDAQ:GCT) rose 10.2% to $34.18.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) gained 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.
    • StepStone Group LP (NASDAQ:STEP) rose 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.

    Losers

    • Aptevo Therapeutics Inc. (NASDAQ:APVO) shares fell 58% to $1.01 after the company priced its $4.6 million public offering.
    • Enlivex Therapeutics Ltd. (NASDAQ:ENLV) fell 54.5% to $1.81. The company announced topline results of its Phase II trial evaluating Allocetra in sepsis.
    • AVITA Medical, Inc. (NASDAQ:RCEL) fell 28.6% to $10.31 after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.
    • Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) fell 19% to $0.3723.
    • Globe Life Inc. (NYSE:GL) fell 14.6% to $89.65.
    • The Lovesac Company (NASDAQ:LOVE) shares fell 14.3% to $20.00 after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.
    • Globe Life Inc. (NYSE:GL) fell 13.7% to $90.56.
    • Meiwu Technology Company Limited (NASDAQ:WNW) shares declined 12.4% to $1.1601 after jumping around 32% on Wednesday.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 12% to $0.7660 after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.
    • CarMax, Inc. (NYSE:KMX) fell 11.7% to $70.02 after the company reported lower-than-expected fourth-quarter earnings.
    • VBI Vaccines Inc. (NASDAQ:VBIV) dipped 11.3% to $0.5641.
    • Nikola Corporation (NASDAQ:NKLA) fell 11.3% to $0.8680. On April 9, Wolfe Research analyst Scott Group initiated coverage on Nikola with a Peer Perform rating.
    • Marin Software Incorporated (NASDAQ:MRIN) declined 10.8% to $0.5798.
    • SolarBank Corporation (NASDAQ:SUUN) fell 9.3% to $5.29. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) fell 9.1% to $2.29.
    • 9F Inc. (NASDAQ:JFU) fell 8.8% to $2.7046.
    • iCoreConnect Inc. (NASDAQ:ICCT) shares fell 8.5% to $1.55 after jumping over 50% on Wednesday.
    • ClearOne, Inc. (NASDAQ:CLRO) declined 8.3% to $1.00. The company recently reported fourth-quarter financial results.
    • Nyxoah S.A. (NASDAQ:NYXH) fell 7.3% to $9.83
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 6.2% to $0.8164.
    • Walker & Dunlop, Inc. (NYSE:WD) fell 5.3% to $87.71 after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.

     

    Now Read This: Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

    Get the next $ACOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AIH
    $AKAN
    $ALPN

    CompanyDatePrice TargetRatingAnalyst
    Fastenal Company
    $FAST
    11/13/2025Underperform → Peer Perform
    Wolfe Research
    Fastenal Company
    $FAST
    11/12/2025$38.00Underperform
    Bernstein
    CarMax Inc
    $KMX
    11/12/2025$28.00Underweight
    Barclays
    CarMax Inc
    $KMX
    11/10/2025$35.00Overweight → Equal-Weight
    Morgan Stanley
    CarMax Inc
    $KMX
    11/7/2025Outperform → Sector Perform
    RBC Capital Mkts
    CarMax Inc
    $KMX
    11/7/2025Buy → Hold
    Needham
    CarMax Inc
    $KMX
    11/6/2025$30.00Neutral → Underweight
    Analyst
    CarMax Inc
    $KMX
    11/6/2025Buy → Hold
    The Benchmark Company
    More analyst ratings

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fastenal upgraded by Wolfe Research

    Wolfe Research upgraded Fastenal from Underperform to Peer Perform

    11/13/25 8:07:01 AM ET
    $FAST
    RETAIL: Building Materials
    Consumer Discretionary

    Bernstein initiated coverage on Fastenal with a new price target

    Bernstein initiated coverage of Fastenal with a rating of Underperform and set a new price target of $38.00

    11/12/25 8:56:00 AM ET
    $FAST
    RETAIL: Building Materials
    Consumer Discretionary

    Barclays initiated coverage on CarMax with a new price target

    Barclays initiated coverage of CarMax with a rating of Underweight and set a new price target of $28.00

    11/12/25 8:55:29 AM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel and CRO Mitchell Robert Brian gifted 2,091 shares and received a gift of 283 shares (SEC Form 4)

    4 - GLOBE LIFE INC. (0000320335) (Issuer)

    11/14/25 2:48:43 PM ET
    $GL
    Life Insurance
    Finance

    Co-Chief Operating Officer Fernandez Jose A sold $13,120,536 worth of shares (211,210 units at $62.12) (SEC Form 4)

    4 - StepStone Group Inc. (0001796022) (Issuer)

    11/13/25 5:53:12 PM ET
    $STEP
    Investment Managers
    Finance

    Director Eastman Stephen L. bought $40,816 worth of shares (1,000 units at $40.82), increasing direct ownership by 5% to 21,000 units (SEC Form 4)

    4 - FASTENAL CO (0000815556) (Issuer)

    11/13/25 1:04:07 PM ET
    $FAST
    RETAIL: Building Materials
    Consumer Discretionary

    $ACOR
    $AIH
    $AKAN
    $ALPN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RETRANSMISSION: Akanda Researching Security Requirements for Full Cultivation License

    Toronto, Ontario--(Newsfile Corp. - November 14, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company currently operates under its hemp cultivation license, Akanda plans to advance toward a full cultivation license for a range of potential THC products and, in parallel, intends to design and commence the build-out of Health Canada–compliant security measures at the site. This planned security program—anticipated to require enhanced perim

    11/14/25 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

    INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah's Chairman and Management, and a convertible bond. Mont-Saint-Guibert, Belgium – November 13, 2025, 2025, 10:11pm CET / 4:11 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced a €22 million private placement of equity, a U.S. $5.6 million registered d

    11/13/25 4:35:46 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Reports Third Quarter 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2025. Recent Financial and Operating Highlights Completed the first commercial implants of U.S. patients, and genera

    11/13/25 4:12:11 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eastman Stephen L. bought $40,816 worth of shares (1,000 units at $40.82), increasing direct ownership by 5% to 21,000 units (SEC Form 4)

    4 - FASTENAL CO (0000815556) (Issuer)

    11/13/25 1:04:07 PM ET
    $FAST
    RETAIL: Building Materials
    Consumer Discretionary

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hsu Hsenghung Sam bought $42,450 worth of shares (1,000 units at $42.45), increasing direct ownership by 12% to 9,000 units (SEC Form 4)

    4 - FASTENAL CO (0000815556) (Issuer)

    10/16/25 3:27:52 PM ET
    $FAST
    RETAIL: Building Materials
    Consumer Discretionary

    $ACOR
    $AIH
    $AKAN
    $ALPN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by StepStone Group Inc.

    SCHEDULE 13G/A - StepStone Group Inc. (0001796022) (Subject)

    11/14/25 12:19:23 PM ET
    $STEP
    Investment Managers
    Finance

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    11/13/25 8:09:22 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form FWP filed by Nyxoah SA

    FWP - Nyxoah SA (0001857190) (Subject)

    11/13/25 8:09:43 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Leadership Updates

    Live Leadership Updates

    View All

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

    – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion.    "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise

    11/4/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Financials

    Live finance-specific insights

    View All

    Nyxoah Reports Third Quarter 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2025. Recent Financial and Operating Highlights Completed the first commercial implants of U.S. patients, and genera

    11/13/25 4:12:11 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    AM Best Affirms Credit Ratings of Globe Life Inc. and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key life/health subsidiaries of Globe Life Inc. (Globe Life) (headquartered in McKinney, TX) (NYSE:GL). Concurrently, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) of Globe Life. AM Best also has affirmed the Short- and Long-Term Issue Credit Ratings (Short-Term IR; Long-Term IR) and the indicative Long-Term IRs on the securities of Globe Life. The outlook of these Credit Ratings (ratings) is stable. (See below for a detailed listing of these companies and ratings.) The ratings reflect Globe Life's balance sheet strength, wh

    11/12/25 3:14:00 PM ET
    $GL
    Life Insurance
    Finance

    Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

    Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively  Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® (Nintedanib) rollout and government procurement-related uncertainty Q3 2025 vs Q3 2024 Highlights Quarterly revenue of $30.6 million, up 20% year-over-year, driven by ETUARY® growth and contributions from sales of Etorel® and Contiva®.GAAP net income doubled to $5.9 million and adjusted net income rose to $8.8 million, reflecting commercial execution and disciplined cost control.Operating income increased 64% to $6.9 million, as operating expenses gr

    11/7/25 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by iCoreConnect Inc.

    SC 13G/A - iCoreConnect Inc. (0001906133) (Subject)

    12/12/24 9:44:00 PM ET
    $ICCT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary